Physician profile
Michael F Saulino
NPI 1821178484
$424,513.13
in general payments reported to CMS, 2019-2025
24 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $34K · 2021: $33K · 2022: $69K · 2023: $71K · 2024: $96K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199K · Travel and Lodging: $33K · Honoraria: $17K · Consulting Fee: $10K · Food and Beverage: $7,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,401.15 |
| Travel and Lodging | $33,011.28 |
| Honoraria | $16,500.00 |
| Consulting Fee | $10,235.25 |
| Food and Beverage | $7,080.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $361,749.47 | 2019-2025 | Dysport |
| Medtronic USA, INC. | $19,142.54 | 2019-2020 | |
| Tersera Therapeutics LLC | $8,771.55 | 2019-2025 | Prialt |
| Abbvie INC. | $8,028.41 | 2022-2025 | Botox |
| Medtronic, INC. | $8,019.80 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Percept Pc Brainsense |
| Piramal Critical Care | $6,191.00 | 2019-2024 | |
| Spr Therapeutics, INC | $4,369.15 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $4,037.01 | 2023-2025 | Exparel, Zilretta, Iovera |
| Amneal Pharmaceuticals LLC | $2,826.15 | 2022-2024 | Lioresal (Baclofen) |
| Sandoz INC. | $477.00 | 2020 | |
| Merz Pharmaceuticals, LLC | $372.72 | 2022-2025 | Xeomin |
| Saol Therapeutics INC. | $95.51 | 2019-2022 | |
| Globus Medical, INC. | $58.32 | 2024 | Excelsius Deformity |
| Neurocrine Biosciences, INC. | $56.37 | 2025 | |
| Stimwave Technologies Incorporated | $56.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $53.37 | 2023 | Nalu Neurostimulation System |
| Grt US Holding, INC. | $49.58 | 2022 | |
| Csl Behring | $47.41 | 2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $34.50 | 2025 | Austedo Xr |
| Flowonix Medical Incorporated | $25.65 | 2020 | |
| Allergan, INC. | $21.60 | 2022 | |
| Ucb, INC. | $17.06 | 2024 | Briviact |
| Sk Life Science, INC. | $12.96 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saulino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.